“If we control itching and eczema, a normal life is possible again”

Atopic dermatitis (AD) continues to pose challenges for dermatology – not least due to its complex immunopathogenesis [1]. In this interview, Prof. Dr. med. Thomas Kündig, University Hospital Zurich, explains which therapeutic goals are being pursued today, how the different generations of Janus kinase inhibitors (JAKi) differ and which patient groups particularly benefit from JAKi in practice.